Michael A. Caligiuri

From Wikipedia, the free encyclopedia
  (Redirected from Michael A. Caliguiri)
Jump to navigation Jump to search
Michael A. Caligiuri
Born(1956-01-08)January 8, 1956[1]
Alma mater
Spouse(s)Ana Maria de Jesús Caligiuri[1]
Scientific career

Michael A. Caliguiri is the president of City of Hope National Medical Center and the physician-in-chief. He was elected president of the American Association for Cancer Research for 2016–2017.[2]


Caliguiri is the former CEO of The James Cancer Hospital and Solove Research Institute and director of the OSU Comprehensive Cancer Center, as well as professor of molecular virology, immunology, medical genetics, and internal medicine and vice president for health sciences at The Ohio State University, where he was a faculty member for 20 years.[3][4] He was deputy director of the James Cancer Hospital and Solove Research Institute from 2003 to 2007, director (2000–2007) and co-director (1997–2000) of the division of hematology and oncology, associate director for clinical research at Ohio State University Comprehensive Cancer Center from 1997 to 2003, and director of the Hematology/Oncology Fellowship Program from 1997 to 2004. He was one of the most highly compensated employees at OSU, earning over a million dollars per year.[5]

He was an attending physician at Roswell Park Memorial Institute from 1990 to 1997 and a professor in the Departments of Medicine and Microbiology/Immunology at Roswell Park Cancer Institute and State University of New York at Buffalo School of Medicine from 1993 to 1997.[6]

He is also the chair of cancer research for the John L. Marakas Nationwide Insurance Enterprise Foundation, a member of the Lymphoma Research Foundation Scientific Advisory Board, and chair of the National Cancer Policy Forum, Institute of Medicine.[7] Caligiuri has served on committees and advisory boards of many organizations, including but not limited to the New York State councils on stem cells and transplantation, USA National Cancer Institute-Sponsored Cooperative Oncology Group, United States of America President's Cancer Panel, Transplantation Society, Society for Natural Immunity, National Institute of Allergy and Infectious Disease, National Cancer Institute, Lymphoma Research Institute, Leukemia Society of America, Institute of Medicine, Friends of Cancer Research, Cure for Lymphoma Foundation, Association of American Cancer Institutes, American Society of Hematology, American Society of Clinical Oncology, American Cancer Society, Association for Research of Childhood Cancer, Memorial Sloan Kettering Cancer Center, Mayo Clinic Cancer Center, and Fox Chase Cancer Center.[1] His work has been funding by the American Cancer Society, Buffalo Medical Foundation, National Cancer Institute, Dr. Louis Sklarow Memorial Fund, Howard Hughes Medical Institute, Leukemia Society of America, Lymphoma Research Foundation, OHIO Third Frontier, Leukemia & Lymphoma Society, and others.[1]


The Caligiuri laboratory focuses on natural killer cells, the Epstein-Barr virus's involvement in tumorigenesis, and hematological cancers such as lymphoma and leukemia.[8]

Honors and awards[edit]


  1. ^ a b c d https://osuwmcdigital.osu.edu/sitetool/sites/intmedhematologypublic/documents/Caligiuri_CV_03_01_2012.pdf
  2. ^ "Michael A. Caligiuri, MD, Named American Association for Cancer Research President-Elect 2016-2017". aacr.org. Retrieved 2016-11-18.
  3. ^ https://cancerletter.com/articles/20171201_2/
  4. ^ "Michael Caligiuri, MD :: Internal Medicine Division of Hematology :: The Ohio State University :: Columbus, OH". internalmedicine.osu.edu. Retrieved 2016-11-18.
  5. ^ "Top 25 List Highest-Paid Public Officials-OSU - Columbus Business First". bizjournals.com. Retrieved 2016-11-18.
  6. ^ a b "President-Elect Candidate Profile: Michael A. Caligiuri". aacr.org. Retrieved 2016-11-18.
  7. ^ "Featured LRF Reseacher: Michael A. Caligiuri, MD - Lymphoma Research Foundation". lymphoma.org. Retrieved 2016-11-18.
  8. ^ "Caligiuri Lab | OSUCCC – James". cancer.osu.edu. Retrieved 2016-11-18.